Citation
Kröger, N, et al. "Reduced-toxicity Conditioning With Treosulfan, Fludarabine and ATG as Preparative Regimen for Allogeneic Stem Cell Transplantation (alloSCT) in Elderly Patients With Secondary Acute Myeloid Leukemia (sAML) or Myelodysplastic Syndrome (MDS)." Bone Marrow Transplantation, vol. 37, no. 4, 2006, pp. 339-44.
Kröger N, Shimoni A, Zabelina T, et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant. 2006;37(4):339-44.
Kröger, N., Shimoni, A., Zabelina, T., Schieder, H., Panse, J., Ayuk, F., Wolschke, C., Renges, H., Dahlke, J., Atanackovic, D., Nagler, A., & Zander, A. (2006). Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplantation, 37(4), 339-44.
Kröger N, et al. Reduced-toxicity Conditioning With Treosulfan, Fludarabine and ATG as Preparative Regimen for Allogeneic Stem Cell Transplantation (alloSCT) in Elderly Patients With Secondary Acute Myeloid Leukemia (sAML) or Myelodysplastic Syndrome (MDS). Bone Marrow Transplant. 2006;37(4):339-44. PubMed PMID: 16415898.
TY - JOUR
T1 - Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
AU - Kröger,N,
AU - Shimoni,A,
AU - Zabelina,T,
AU - Schieder,H,
AU - Panse,J,
AU - Ayuk,F,
AU - Wolschke,C,
AU - Renges,H,
AU - Dahlke,J,
AU - Atanackovic,D,
AU - Nagler,A,
AU - Zander,A,
PY - 2006/1/18/pubmed
PY - 2006/6/10/medline
PY - 2006/1/18/entrez
SP - 339
EP - 44
JF - Bone marrow transplantation
JO - Bone Marrow Transplant
VL - 37
IS - 4
N2 - We investigated a dose-reduced conditioning regimen consisting of treosulfan and fludarabine followed by allogeneic stem cell transplantation (SCT) in 26 patients with secondary AML or MDS. Twenty patients were transplanted from matched or mismatched unrelated donors and six from HLA-identical sibling donors. The median age of the patients was 60 years (range, 44-70). None of the patients was eligible for a standard myeloablative preparative regimen. No graft-failure was observed, and leukocyte and platelet engraftment were observed after a median of 16 and 17 days, respectively. Acute graft-versus-host disease (GvHD) grade II-IV was seen in 23% and severe grade III GvHD in 12% of the patients. No patients experienced grade IV acute GvHD. Chronic GvHD was noted in 36% of the patients, which was extensive disease in 18%. The 2-year cumulative incidence of relapse was 21%. The relapse rate was higher in patients beyond CR1 or with intermediate two or high risk MDS (P = 0.02). The treatment-related mortality at day 100 was 28%. The 2-year estimated overall and disease-free survival was 36-34%, respectively. No difference in survival was seen between unrelated and related SCT.
SN - 0268-3369
UR - https://www.unboundmedicine.com/medline/citation/16415898/Reduced_toxicity_conditioning_with_treosulfan_fludarabine_and_ATG_as_preparative_regimen_for_allogeneic_stem_cell_transplantation__alloSCT__in_elderly_patients_with_secondary_acute_myeloid_leukemia__sAML__or_myelodysplastic_syndrome__MDS__
L2 - https://doi.org/10.1038/sj.bmt.1705259
DB - PRIME
DP - Unbound Medicine
ER -
